Development and evaluation of cancer differentiation analysis technology: a novel biophysics-based cancer screening method: Expert Review of Molecular Diagnostics: Vol 0, No 0

Development and evaluation of cancer differentiation analysis technology: a novel biophysics-based cancer screening method: Expert Review of Molecular Diagnostics: Vol 0, No 0 (tandfonline.com)

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022

Read the full article

Sign up for the Anpac Bio newsletter and receive our latest news.

Quick Links

Contact Information

Anpac Technology USA (Anpac Bio)
3 Spring House Innovation Park, Suite 150
Ambler, PA 19002

Email: [email protected]

Phone Number: +1 (267) 810-6776

Anpac Bio-Medical Science Co., Ltd.

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.

©2021 Anpac Bio-Medical Science Co., Ltd.
Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published...AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests...